<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02960464</url>
  </required_header>
  <id_info>
    <org_study_id>HSMarcelina</org_study_id>
    <nct_id>NCT02960464</nct_id>
  </id_info>
  <brief_title>tDCS for Treatment of Depression in Parkinson's Disease</brief_title>
  <official_title>Transcranial Direct Current Stimulation for Treatment of Depression in Parkinson's Disease, a Randomized Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Santa Marcelina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Santa Marcelina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of possible benefits of transcranial direct current stimulation (tDCS) as a
      treatment of depression in patients with Parkinson's Disease, through a randomized
      placebo-controlled clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We aim to investigate the effects of transcranial direct current stimulation (tDCS) as
      treatment for depression in patients with Parkinson's Disease. We have designed a clinical
      trial in which volunteers that fulfill inclusion criteria will receive 15 sessions of tDCS
      during 1 week (3 sessions a day, with 30 minutes interval in between). Subjects will be
      randomly allocated into two groups, one that will receive the real intervention (active) and
      the other that will receive the placebo intervention (sham). The collaborator in charge of
      administering the session will not participate in the evaluations, keeping both subjects and
      evaluators blinded to the nature of the sessions. Subjects will be evaluated at baseline, and
      after the end of sessions, 1 week, 4 weeks and 8 weeks, the latter being the main outcome.

      We aim to enroll 50 subjects, 25 for each arm. The sample size calculation took into
      consideration previous clinical trials using tDCS for depression in different settings.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Ã…sberg Depression Rating Scale</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examination</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric Depression Scale -15</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parkinson's Disease Questionnaire - 39</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lille apathy rating scale</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative EEG</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Idiopathic Parkinson Disease</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active sessions will involve the placement of the anode over the scalp corresponding to the F3 (10-20 EEG system), and cathode over F4. Current intensity will be 2mA, and the stimulation will last for 20 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham stimulation will follow the same procedure as the Active, however after 30 seconds of stimulation, the current is turned off, mimicking the initial sensation of the tDCS session but providing no clinical or physiological effect.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial direct current stimulation</intervention_name>
    <arm_group_label>Active Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Transcranial direct current stimulation</intervention_name>
    <arm_group_label>Sham Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic Parkinson's Disease

          -  Geriatric Depression Scale - 15 higher that 5

          -  Major Depression Disorder

        Exclusion Criteria:

          -  CNS disease other than Parkinson's Disease (i.e. epilepsy, stroke)

          -  Mental disorder other than depression on anxiety disorder (i.e. bipolar disorder,
             schizophrenia)

          -  Previous neurosurgical intervention (i.e. DBS)

          -  Current use of antidepressant drug

          -  High suicidality risk

          -  Limited capacity of understanding written and spoken Portuguese
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Sheila Rocha, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Santa Marcelina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamana Barbosa</last_name>
    <phone>2070-6000</phone>
    <email>jamana.bp@ig.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Santa Marcelina</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Gordon, MD</last_name>
      <email>dr.pedrogordon@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Maria Sheila Rocha, MD, PhD</last_name>
      <email>msrocha@uol.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Pedro Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Sheila Rocha, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jamana Barbosa</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2016</study_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Santa Marcelina</investigator_affiliation>
    <investigator_full_name>Pedro Caldana Gordon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Parkinson Disease</keyword>
  <keyword>Depression</keyword>
  <keyword>Transcranial Direct Current Stimulation</keyword>
  <keyword>Neuromodulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

